Already have an ACS ID? Log in
Renew your membership, and continue to enjoy these benefits.
Already an ACS Member? Log in here
Choose the membership that is right for you. Discount will be applied automatically at checkout.
Enjoy these benefits no matter which membership you pick.
Most Popular in Business
Alnylam Pharmaceuticals, a developer of RNA interference (RNAi) therapies, is partnering with CAMP4 Therapeutics to find new drug targets for a rare liver disease. CAMP4, which announced raising $30 million in series A financing in May 2018, uses computational tools to understand the rules dictating how genes are regulated—turned up or down—in cell types across the body. Because Alnylam’s RNAi drugs work by effectively turning genes down, the partnership may provide the first big test of CAMP4’s technology.
This article has been sent to the following recipient: